Long-term remote ischemic preconditioning after a heart attack
Official title: Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction
Run by Henan Institute of Cardiovascular Epidemiology · NCT07181356 · Data updated 2026-11-12
This trial will test whether daily brief arm blood‑flow restriction after a recent heart attack can lower the chance of major heart and brain events over the following year for people treated for acute myocardial infarction.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2146 (estimated) |
| Sponsor | Henan Institute of Cardiovascular Epidemiology Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2028 |
| Registry record updated | September 18, 2025 |
| Trial ID | NCT07181356 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with acute myocardial infarction by the Fourth Universal Definition who can tolerate upper‑limb RIPC and meet the study's inclusion/exclusion criteria are ideal candidates.
✕Probably not a fit
Patients with severe liver or renal dysfunction, uncontrolled severe hypertension, aortic or major coronary structural disease, those taking drugs that affect microcirculation (like nicorandil), pregnant people, or anyone who cannot tolerate RIPC are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial will enroll about 2,146 patients with acute myocardial infarction and randomly assign 1,073 to daily upper‑limb remote ischemic preconditioning (RIPC) and 1,073 to usual care. RIPC consists of repeated brief cycles of arm blood‑flow restriction applied after admission and continued through follow‑up. Baseline labs, ECG, and ultrasound are recorded, and major adverse cardiovascular and cerebrovascular events (MACCE) and a composite PoCE endpoint are collected at 12 months, mainly by telephone follow‑up. The control arm receives standard medical management without the RIPC intervention.
Why it matters
Potential benefit: If successful, a simple, low‑cost daily RIPC protocol could reduce major cardiovascular and cerebrovascular events and improve one‑year outcomes after acute myocardial infarction.
How similar studies have gone: Prior short‑term RIPC studies around PCI have shown mixed results, and long‑term daily RIPC after AMI is relatively untested in large randomized trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the "Global Unified Definition of Fourth Myocardial Infarction" Exclusion Criteria: * The patients could not tolerate RIPC or RIPerC * Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases * The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively * severe liver dysfunction (bilirubin \> 20 mmol / L, prothrombin time \> 2.0 ratio) * Severe renal insufficiency (GFR \< 30 ml / min / 1.73 m2); * patients taking nicorandil and other drugs affecting microcirculation * pregnant
Where it's running
-
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, China Recruiting
Study contacts
- Study coordinator: Muwei LI
- Email: lmw0207@163.com
- Phone: 13838083966
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients
This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.
-
Adenosine given before primary PCI to reduce no-reflow in STEMI patients.
See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.
-
Subclinical depression in people after a first heart attack (SUBDIMA25)
This project will test how common mild depressive symptoms are in adults hospitalized for a first heart attack and whether those symptoms relate to biomarkers, heart function, and recovery over the next year.
-
Long-term follow-up after Hearticellgram-AMI treatment
We will follow people who got one dose of Hearticellgram-AMI after a heart attack for up to 60 months to see if the treatment stays safe.
-
Using wearable devices to monitor heart attack patients
This study tests whether wearable devices can help monitor heart attack patients in the hospital to improve their care and predict their recovery.
-
Assessing heart tissue damage in patients with heart aneurysms after a heart attack
This study is testing how heart tissue damage looks in patients with heart aneurysms after a heart attack using special imaging to see if it helps understand their condition better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.